Skip to main content
Premium Trial:

Request an Annual Quote

OraSure Technologies: Robert McMahon

OraSure Technologies said it has appointed Robert McMahon to its board of directors effective July 31. He will serve as a Class II Director with an initial term expiring at OraSure's 2026 annual meeting of stockholders. McMahon is senior VP and CFO for Agilent Technologies, and he has more than 30 years of experience as a financial leader. He previously spent four years as CFO at Hologic and more than 20 years in leadership positions at Johnson & Johnson.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.